EP1140163A2 - Combination of hepatitis b vaccine with antiviral agents - Google Patents

Combination of hepatitis b vaccine with antiviral agents

Info

Publication number
EP1140163A2
EP1140163A2 EP99965531A EP99965531A EP1140163A2 EP 1140163 A2 EP1140163 A2 EP 1140163A2 EP 99965531 A EP99965531 A EP 99965531A EP 99965531 A EP99965531 A EP 99965531A EP 1140163 A2 EP1140163 A2 EP 1140163A2
Authority
EP
European Patent Office
Prior art keywords
hepatitis
pharmaceutical pack
vaccine
antiviral agent
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99965531A
Other languages
German (de)
French (fr)
Inventor
Gillian F. SmithKline Beecham Pharm. ATKINSON
R.J. SmithKline Beecham Consumer Healthcare BOON
P.G. SmithKline Beecham Bio. S.A. VANDEPAPELIERE
M.A.C. SmithKline Beecham Biol. S.A. WETTENDORFF
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of EP1140163A2 publication Critical patent/EP1140163A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention relates to the use of a nucleoside analogue active against hepatitis B virus (HBN). or another class of antiviral active against HBN, such as ⁇ interferon or a nucleotide analogue and an HBN vaccine in the treatment of hepatitis B virus infections.
  • HBN hepatitis B virus
  • Chronic hepatitis B virus (HBV) infection for which there is currently no effective cure, constitutes a global public health problem of enormous dimensions.
  • Chronic carriers of HBN estimated to number more than 300 million world-wide, are at risk for development of chronic active hepatitis, cirrhosis and primary heptocellular carcinoma.
  • EP-A-388049 (Beecham Group p. I.e.), discloses the use of penciclovir/famciclovir in the treatment of hepatitis B virus infection. All references herein to penciclovir/famciclovir include pharmaceutically acceptable salts, such as the hydrochloride, and solvates, such as hydrates.
  • EP-A-494119 discloses the use of 1 ,3-oxathiolane nucleoside analogues, including lamivudine. in treatment of Hepatitis B.
  • the present invention provides a pharmaceutical pack comprising as active ingredients (1) an antiviral agent active against hepatitis B virus and (2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential use.
  • pharmaceutical pack is meant a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients.
  • the pack may for example comprise metal or plastic foil, such as a blister pack.
  • the pack or dispenser device may be accompanied by instructions for administration. Where the antiviral agent and the HBN vaccine are intended for administration as two separate compositions these may be presented in the form of, for example, a twin pack.
  • the invention may be used for either the treatment or prophylaxis of hepatitis B infections. The invention is most particularly of value for treatment, for example, of chronic hepatitis B infections.
  • the antiviral agent as used in the pharmaceutical pack is a nucleoside agent.
  • the antiviral agent is a nucleotide agent Suitable agents for use in the invention include penciclovir, famciclovir, lamivudine, ganciclovir, lobucavir, adefovir, ⁇ bavi ⁇ n, BMS200,475, vidarabin or ARA-AMP
  • Preferred nucleoside analogues include penciclovir, famciclovir and lamivudine
  • a further potential antiviral agent is an interferon Alpha - interferon is especially preferred.
  • nucleoside analogues may be obtained from well known pharmaceutical industry references, such as "Pharmaprojects", PJB publications Limited, Richmond, Surrey, U K or from 'R & D Focus', isssued by IMS World publications, 364 Euston Road, London NW1 3BL
  • references to an anti-hepatitis B virus nucleoside analogue include solvates such as hydrates.
  • the anti-hepatitis B virus nucleoside or nucleotide analogue and HBV vaccine of this invention may be administered in combination with other pharmacologically active agents, in particular, other antivirals
  • the vaccine for the prophylaxis and/or treatment of hepatitis B infection includes all vaccines containing HBV antigens (such as surface antigen, core and polymerase) and therapeutic vaccines.
  • the hepatitis B virus antigen is the hepatitis B surface antigen (HbsAg).
  • HbsAg hepatitis B surface antigen
  • Hepatitis B surface antigen' or ⁇ BsAg' includes any HBsAg antigen or immunogenic derivative thereof, particularly fragments thereof, displaying the antigenicity of HBV surface antigen. It will be understood that in addition to the 226 amino acid sequence of the HBsAg S antigen (see Tiollais et. al. Nature, 317, 489 (1985) and references therein) HBsAg as herein described may, if desired, contain all or part of a pre-S sequence as described in the above references and in EP-A- 0 278 940. HBsAg as herein described can also refer to variants, for example the 'escape mutant' described in WO 91/14703.
  • the HBsAg may comprise a protein described as L* in European Patent Application Number 0 414 374, that is to say a protein, the amino acid sequence of which consists of parts of the amino acid sequence of the hepatitis B virus large (L) protein (ad or ay subtype), characterised in that the amino acid sequence of the protein consists of either:
  • HBsAg may also refer to polypeptides described in EP 0 198 474 or EP 0 304 578. Normally the HBsAg will be in particle form. It may comprise S protein alone or may be as composite particles, for example (S, L*) wherein L* is as defined above and S denotes the S-protein of hepatitis B surface antigen. A preferred hepatitis B antigen is this composite particle, defined as S,L*.
  • a further preferred hepatitis B antigen is the 226 amino acid sequence of the HBV surface antigen, in particle form.
  • Such a vaccine may advantageously include a pharmaceutically acceptable excipient such as a suitable adjuvant.
  • suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate (as described in WO93/24148), but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
  • the hepatitis B virus may be formulated with strong adjuvant systems.
  • the adjuvant composition induces an immune response comprising THl aspects.
  • Suitable adjuvant systems include, for example a combination of monophosphoryl lipid A, preferably 3- de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salts.
  • a vaccine comprising hepatitis B surface antigen in conjunction with 3D-MPL was described in European Patent Application 0 633 784.
  • An enhanced system involves the combination of monophosphoryl lipid A and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
  • CpG containing oligonucleotides see University of Iowa; WO9602555.
  • a vaccine comprising an HBV antigen, adjuvanted with a monophosphoryl lipid A or derivative thereof.
  • the vaccine additional comprises a saponin, more preferably QS21.
  • the formulation additional comprises an oil in water emulsion and tocopherol.
  • the present invention also provides a method of treatment and/or prophylaxis of hepatitis B virus infections, which comprises administering to a human or animal subject, suffering from or susceptible to Hepatitis B virus infection, either either simultaneously or sequentially in any order, a safe and effective amount of 1) an antiviral agent active against hepatitis B virus and 2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection.
  • the antiviral such as penciclovir/famciclovir and the HBV vaccine or a pharmaceutically acceptable salt or ester thereof, may be co-administered in the form of two separate pharmaceutical compositions for simultaneous or sequential use. Normally the active ingredients will be administered separately according to the normal dosage and administration regimen for the ingredients given alone.
  • Commencement of administration may be either with the vaccine or the antiviral.
  • the present invention also provides for the use of an antiviral compound in the manufacture of a medicament for the treatment of patients already primed with a hepatitis B vaccine and suffering from a hepatitis B virus infection.
  • the invention further provides for the use of a hepatitis B vaccine in the manufacture of a medicament for the treatment of patients already primed with an antiviral compound and suffering from a hepatitis B virus infection.
  • the preferred antiviral is a nucleoside analogue, most preferably penciclovir/famciclovir or lamivudine.
  • Preferred hepatitis B vaccines are identified hereinabove.
  • the unit doses of the nucleoside or nucleotide analogue may be administered, for example, 1 to 4 times per day.
  • the exact dose will depend on the route of administration and the severity of the condition being treated, and it will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient and immunocompromised patients may require an increased dosage.
  • Vaccines are administered in multiple doses at various intervals. This is usually 6 - 12 doses at biweekly or monthly intervals.
  • the preferred ingredients in the pharmaceutical pack when administered simultaneously are given as separate preparations, for example, as vaccinations in each arm. It is however possible to consider simultaneous administration by mixing the ingredients before administration.
  • the ingredients may be given enterally, such as orally or parenterally (e.g. intramuscularly or, more particularly, intravenously).
  • compositions for oral use such as tablets and capsules may be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, micro -crystalline cellulose or calcium hydrogen phosphate); lubricant (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agent (e.g. sodium lauryl sulphate). Tablets may be coated by methods well known in the art.
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose
  • fillers e.g. lactose, micro -crystalline cellulose or calcium hydrogen phosphate
  • lubricant e.g. magnesium stearate, talc or silica
  • disintegrants e.
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-g-hydroxybenzoates or sorbic acid).
  • the preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of one or both active ingredients.
  • compositions may be presented in a form suitable for bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form e.g. in syringes, ampoules or in multi-dose containers, with an added preservative.
  • the active antiviral agent may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredients may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the active antiviral agents may be formulated as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
  • the active antiviral agents of the invention may be prepared according to conventional techniques well known in the pharmaceutical industry.
  • the lamivudine/penciclovir/famciclovir may be admixed, if desired, with suitable excipients.
  • Tablets may be prepared, for example, by direct compression of such a mixture.
  • Capsules may be prepared by filling the blend along with suitable excipients into gelatin capsules, using a suitable filling machine.
  • Controlled release forms for oral or rectal administration may be formulated in a conventional manner associated with controlled release forms.
  • Anti-hepatitis B virus nucleoside analogues may be identified by standard methods, such as tests involving studies in in vitro primary duck hepatocytye cultures infected with the duck hepatitis B virus (DHBV). Changes in the levels of preSl and/or viral
  • analogues may be identified by the ability to interfere with normal acylation of synthetic peptides representing the N-terminal amino acids of DHBV or hepatitis B viruses of man, woodchucks, ground squirrels or other animals.
  • the following vaccine composition was employed.
  • the HBV surface antigen was equivalent to the antigen employed in the commercially available Engerix-B vaccine TM (Smithkline Beecham Biologicals), except that it was lyophilised. Lyophilized Ag:
  • Adjuvant system oil in water emulsion: 250 ⁇ l
  • Lamivudine (Zeffix TM, Glaxo Wellcome) was administered daily by oral capsule to three male and three female dogs at a dose level of 100 mg/dog/day for 6 weeks. On Days 14, 28 and 42 the HBs/adjuvant vaccine as described above was administered by intramuscular injection immediately before administration of Lamivudine. Blood samples were taken at pre-dose, 0.5, 0.75, 1, 2, 4, 6, 8, 12 and 24 hours after dosing of Lamivudine on Days 7, 14, 28 and 42. The separated plasma was frozen at -20°C prior to despatch to Pharma Bio-Research for analysis of plasma concentrations of Lamivudine.
  • Plasma concentrations of Lamivudine in samples taken up to 24 hours post-dose were measured by Pharma Bio-Research.
  • the maximum mean plasma concentrations of Lamivudine occurred at 2 hours post- dose on all the sampling days except for females on Day 7 where the maximum mean plasma Lamivudine concentration occurred at 1 hour post-dose. On Day 28, the maximum mean plasma concentrations of Lamivudine were lower than those values on Day 7, 14 and 42. After the maximum, the mean plasma concentrations of Lamivudine declined in an apparently biexponential manner.
  • Cmax Mean maximum plasma concentrations (Cmax) of Lamivudine and the areas under the plasma Lamivudine concentration-time curves estimated up to 24 hours post-dose (AUC 24 ) on Days 7, 14, 28 and 42 are summarised below with standard deviations in parentheses:
  • Tmax The times at which the maximum plasma concentrations occurred (Tmax) in individual dogs were generally 2 hours, and in the range 0.75 to 4 hours and appeared to be independent of administration of the HBs vaccine.
  • Plasma concentrations of Lamivudine were quantifiable in male animal numbers 71 and 73 and in female animal number 70 at all time points on Days 7, 14, 28 and 42, therefore, these animals were continuously exposed to quantifiable concentrations of Lamivudine during a dosing interval.
  • Lamivudine was generally slightly lower than that in male dogs. However, there was no statistically significant evidence for any sex-related differences in systemic exposure (p > 0.57). On Days 14, 28 and 42 the rate (Cmax) and extent (AUC 24 ) of systemic exposure of dogs to Lamivudine were generally similar to those values on Day 7, however, the
  • the mean accumulation ratios were generally close to or less than one indicating that little or no accumulation of Lamivudine occurred following administration of HBs vaccine.
  • the terminal rate constants, and corresponding terminal half-lives, of Lamivudine on Days 7, 14, 28 and 42 are presented in Tables 5 - 8.
  • the terminal rate constant, where it could be calculated ranged from 0.3239 to 0.1364 hours " ' corresponding to a terminal half-life of Lamivudine of 2.1 to 5.1 hours.
  • HBs Hep 286
  • Antigen and antibody solutions were used at 100 ⁇ l per well.
  • Antigen was diluted at a final concentration of 1 ⁇ g/ml in PBS and was adsorbed overnight at 4°C to the wells of 96 wells microtiter plates (Maxisorb Immuno-plate, Nunc, Denmark). The plates were then incubated for lhr 30 min at 37°C with PBS containing 5% non fat powder milk and 0.1% Tween 20.
  • TMB Tetramethyl benzidine
  • the mid-point average titers at the different timepoint are the respectively 25 on Day 0 (arbitrary 1/2 of first dilution), 383 on day 29 and 5321 on day 43. This clearly indicate the induction of an immune response.

Abstract

This invention provides a pharmaceutical pack comprising as active ingredients (1) an antiviral agent active against hepatitis B virus and (2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential use. Preferred components are a nucleoside analogue as the antiviral agent, together with a hepatitis B virus vaccine which comprises a hepatitis B virus surface antigen.

Description

NOVEL TREATMENT
This invention relates to the use of a nucleoside analogue active against hepatitis B virus (HBN). or another class of antiviral active against HBN, such as γ interferon or a nucleotide analogue and an HBN vaccine in the treatment of hepatitis B virus infections.
Chronic hepatitis B virus (HBV) infection, for which there is currently no effective cure, constitutes a global public health problem of enormous dimensions. Chronic carriers of HBN, estimated to number more than 300 million world-wide, are at risk for development of chronic active hepatitis, cirrhosis and primary heptocellular carcinoma.
EP-A-388049 (Beecham Group p. I.e.), discloses the use of penciclovir/famciclovir in the treatment of hepatitis B virus infection. All references herein to penciclovir/famciclovir include pharmaceutically acceptable salts, such as the hydrochloride, and solvates, such as hydrates.
EP-A-494119 (IAF Biochem. International Inc.) discloses the use of 1 ,3-oxathiolane nucleoside analogues, including lamivudine. in treatment of Hepatitis B.
The present invention provides a pharmaceutical pack comprising as active ingredients (1) an antiviral agent active against hepatitis B virus and (2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential use.
By pharmaceutical pack is meant a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Where the antiviral agent and the HBN vaccine are intended for administration as two separate compositions these may be presented in the form of, for example, a twin pack. The invention may be used for either the treatment or prophylaxis of hepatitis B infections. The invention is most particularly of value for treatment, for example, of chronic hepatitis B infections.
In one aspect, the antiviral agent as used in the pharmaceutical pack is a nucleoside agent. In a further aspect the antiviral agent is a nucleotide agent Suitable agents for use in the invention include penciclovir, famciclovir, lamivudine, ganciclovir, lobucavir, adefovir, πbaviπn, BMS200,475, vidarabin or ARA-AMP Preferred nucleoside analogues include penciclovir, famciclovir and lamivudine
A further potential antiviral agent is an interferon Alpha - interferon is especially preferred.
Information with respect to structure and activity of nucleoside analogues may be obtained from well known pharmaceutical industry references, such as "Pharmaprojects", PJB publications Limited, Richmond, Surrey, U K or from 'R & D Focus', isssued by IMS World publications, 364 Euston Road, London NW1 3BL
References to an anti-hepatitis B virus nucleoside analogue, including the specific compounds mentioned hereinbefore and salts thereof, include solvates such as hydrates.
Examples of pharmaceutically acceptable salts are as described in the aforementioned Patent reference in the name of Beecham Group p I.e. and references quoted therein, the subject matter of which are incorporated herein by reference.
It will be appreciated that the anti-hepatitis B virus nucleoside or nucleotide analogue and HBV vaccine of this invention may be administered in combination with other pharmacologically active agents, in particular, other antivirals In this invention the vaccine for the prophylaxis and/or treatment of hepatitis B infection includes all vaccines containing HBV antigens (such as surface antigen, core and polymerase) and therapeutic vaccines.
In one aspect of the invention the hepatitis B virus antigen is the hepatitis B surface antigen (HbsAg). The preparation of Hepatitis B surface antigen is well documented. See for example, Harford et. al. in Develop. Biol. Standard 54, page 125 (1983), Gregg et. al. in Biotechnology, 5, page 479 (1987), EP-A- 0 226 846, EP-A-0 299 108 and references therein.
As used herein the expression 'Hepatitis B surface antigen' or ΗBsAg' includes any HBsAg antigen or immunogenic derivative thereof, particularly fragments thereof, displaying the antigenicity of HBV surface antigen. It will be understood that in addition to the 226 amino acid sequence of the HBsAg S antigen (see Tiollais et. al. Nature, 317, 489 (1985) and references therein) HBsAg as herein described may, if desired, contain all or part of a pre-S sequence as described in the above references and in EP-A- 0 278 940. HBsAg as herein described can also refer to variants, for example the 'escape mutant' described in WO 91/14703. In a further aspect the HBsAg may comprise a protein described as L* in European Patent Application Number 0 414 374, that is to say a protein, the amino acid sequence of which consists of parts of the amino acid sequence of the hepatitis B virus large (L) protein (ad or ay subtype), characterised in that the amino acid sequence of the protein consists of either:
(a) residues 12 - 52, followed by residues 133 - 145, followed by residues 175 - 400 of the said L protein; or
(b) residue 12, followed by residues 14 - 52, followed by residues 133 - 145, followed by residues 175 - 400 of the said L protein.
HBsAg may also refer to polypeptides described in EP 0 198 474 or EP 0 304 578. Normally the HBsAg will be in particle form. It may comprise S protein alone or may be as composite particles, for example (S, L*) wherein L* is as defined above and S denotes the S-protein of hepatitis B surface antigen. A preferred hepatitis B antigen is this composite particle, defined as S,L*.
A further preferred hepatitis B antigen is the 226 amino acid sequence of the HBV surface antigen, in particle form.
Such a vaccine may advantageously include a pharmaceutically acceptable excipient such as a suitable adjuvant. Suitable adjuvants include an aluminium salt such as aluminium hydroxide gel (alum) or aluminium phosphate (as described in WO93/24148), but may also be a salt of calcium, iron or zinc, or may be an insoluble suspension of acylated tyrosine, or acylated sugars, cationically or anionically derivatised polysaccharides, or polyphosphazenes.
Advantageously, the hepatitis B virus may be formulated with strong adjuvant systems. Thus in the formulation of the invention, it is preferred that the adjuvant composition induces an immune response comprising THl aspects. Suitable adjuvant systems include, for example a combination of monophosphoryl lipid A, preferably 3- de-O-acylated monophosphoryl lipid A (3D-MPL) together with an aluminium salts. A vaccine comprising hepatitis B surface antigen in conjunction with 3D-MPL was described in European Patent Application 0 633 784.
An enhanced system involves the combination of monophosphoryl lipid A and a saponin derivative particularly the combination of QS21 and 3D-MPL as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739.
Other known adjuvants which may be included are CpG containing oligonucleotides (see University of Iowa; WO9602555).
In a preferred embodiment of the present invention there is provided a vaccine comprising an HBV antigen, adjuvanted with a monophosphoryl lipid A or derivative thereof. Preferably the vaccine additional comprises a saponin, more preferably QS21.
Preferably the formulation additional comprises an oil in water emulsion and tocopherol.
A particularly potent adjuvant formulation involving QS21, 3D-MPL & tocopherol in an oil in water emulsion is described in WO 95/17210.
The present invention also provides a method of treatment and/or prophylaxis of hepatitis B virus infections, which comprises administering to a human or animal subject, suffering from or susceptible to Hepatitis B virus infection, either either simultaneously or sequentially in any order, a safe and effective amount of 1) an antiviral agent active against hepatitis B virus and 2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection.
The antiviral such as penciclovir/famciclovir and the HBV vaccine or a pharmaceutically acceptable salt or ester thereof, may be co-administered in the form of two separate pharmaceutical compositions for simultaneous or sequential use. Normally the active ingredients will be administered separately according to the normal dosage and administration regimen for the ingredients given alone.
Commencement of administration may be either with the vaccine or the antiviral.
The present invention also provides for the use of an antiviral compound in the manufacture of a medicament for the treatment of patients already primed with a hepatitis B vaccine and suffering from a hepatitis B virus infection. The invention further provides for the use of a hepatitis B vaccine in the manufacture of a medicament for the treatment of patients already primed with an antiviral compound and suffering from a hepatitis B virus infection. The preferred antiviral is a nucleoside analogue, most preferably penciclovir/famciclovir or lamivudine. Preferred hepatitis B vaccines are identified hereinabove. The unit doses of the nucleoside or nucleotide analogue may be administered, for example, 1 to 4 times per day. The exact dose will depend on the route of administration and the severity of the condition being treated, and it will be appreciated that it may be necessary to make routine variations to the dosage depending on the age and weight of the patient and immunocompromised patients may require an increased dosage.
Vaccines are administered in multiple doses at various intervals. This is usually 6 - 12 doses at biweekly or monthly intervals.
The preferred ingredients in the pharmaceutical pack when administered simultaneously are given as separate preparations, for example, as vaccinations in each arm. It is however possible to consider simultaneous administration by mixing the ingredients before administration. The ingredients may be given enterally, such as orally or parenterally (e.g. intramuscularly or, more particularly, intravenously).
The anitviral agents of the invention may be formulated as a tablet prepared by conventional means. Compositions for oral use such as tablets and capsules may be prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, micro -crystalline cellulose or calcium hydrogen phosphate); lubricant (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agent (e.g. sodium lauryl sulphate). Tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-g-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.
Preparations for oral administration may be suitably formulated to give controlled release of one or both active ingredients.
For parenteral administration the compositions may be presented in a form suitable for bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in syringes, ampoules or in multi-dose containers, with an added preservative.
The active antiviral agent may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredients may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
For rectal administration the active antiviral agents may be formulated as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.
The active antiviral agents of the invention may be prepared according to conventional techniques well known in the pharmaceutical industry. Thus, for example, the lamivudine/penciclovir/famciclovir may be admixed, if desired, with suitable excipients. Tablets may be prepared, for example, by direct compression of such a mixture. Capsules may be prepared by filling the blend along with suitable excipients into gelatin capsules, using a suitable filling machine. Controlled release forms for oral or rectal administration may be formulated in a conventional manner associated with controlled release forms.
Anti-hepatitis B virus nucleoside analogues may be identified by standard methods, such as tests involving studies in in vitro primary duck hepatocytye cultures infected with the duck hepatitis B virus (DHBV). Changes in the levels of preSl and/or viral
DNA in cultures treated with such anologs would indicate activity. Alternatively, analogues may be identified by the ability to interfere with normal acylation of synthetic peptides representing the N-terminal amino acids of DHBV or hepatitis B viruses of man, woodchucks, ground squirrels or other animals.
EXAMPLES
Hepatitis B surface antigen vaccine/Lamivudine pharmacokinetics interaction study in dogs
METHODS
The following vaccine composition was employed. The HBV surface antigen was equivalent to the antigen employed in the commercially available Engerix-B vaccine ™ (Smithkline Beecham Biologicals), except that it was lyophilised. Lyophilized Ag:
HBsAg lOOμg
Sucrose 12.6 mg
NaCl 20.3mM NaH2PO4 / Na2HPO4 1.35 mM
Adjuvant system: oil in water emulsion: 250 μl
- Squalene 10.7 mg
- DL -tocopherol 1 1.9 mg
- polyoxyethylenesorbitan monooleate (Tween 80) 4.8 mg
Monophosphoryl lipid A 100 μg
QS21 100 μg
Water for injection q.s. ad 0.5 ml
Na2HPO4 575 μg
KH2PO4 100 μg
KC1 100 μg
NaCl 4mg
PH 6.8 +/- 0.2 Lamivudine (Zeffix ™, Glaxo Wellcome) was administered daily by oral capsule to three male and three female dogs at a dose level of 100 mg/dog/day for 6 weeks. On Days 14, 28 and 42 the HBs/adjuvant vaccine as described above was administered by intramuscular injection immediately before administration of Lamivudine. Blood samples were taken at pre-dose, 0.5, 0.75, 1, 2, 4, 6, 8, 12 and 24 hours after dosing of Lamivudine on Days 7, 14, 28 and 42. The separated plasma was frozen at -20°C prior to despatch to Pharma Bio-Research for analysis of plasma concentrations of Lamivudine.
Sera were collected on days 0, 29 and 43 for anti-HBs antibody evaluation.
RESULTS
Lamivudine pharmacokinetics
Blood samples were taken on Days 7, 14, 28 and 42 of a 6-week toxicity study in order to assess the systemic exposure of male and female dogs to Lamivudine following daily oral administration of Lamivudine at a dose level of 100 mg/dog/day and intramuscular administration of HBs vaccine on Days 14, 28 and 42 immediately before administration of Lamivudine. Plasma concentrations of Lamivudine in samples taken up to 24 hours post-dose were measured by Pharma Bio-Research.
The maximum mean plasma concentrations of Lamivudine occurred at 2 hours post- dose on all the sampling days except for females on Day 7 where the maximum mean plasma Lamivudine concentration occurred at 1 hour post-dose. On Day 28, the maximum mean plasma concentrations of Lamivudine were lower than those values on Day 7, 14 and 42. After the maximum, the mean plasma concentrations of Lamivudine declined in an apparently biexponential manner.
Mean maximum plasma concentrations (Cmax) of Lamivudine and the areas under the plasma Lamivudine concentration-time curves estimated up to 24 hours post-dose (AUC24) on Days 7, 14, 28 and 42 are summarised below with standard deviations in parentheses:
Cmax (ng/ml)
AUC24 (ng.h/ml)
The times at which the maximum plasma concentrations occurred (Tmax) in individual dogs were generally 2 hours, and in the range 0.75 to 4 hours and appeared to be independent of administration of the HBs vaccine.
Plasma concentrations of Lamivudine were quantifiable in male animal numbers 71 and 73 and in female animal number 70 at all time points on Days 7, 14, 28 and 42, therefore, these animals were continuously exposed to quantifiable concentrations of Lamivudine during a dosing interval.
The rate (Cmax) of systemic exposure of female dogs to Lamivudine was slightly higher than that in male dogs. The extent (AUC24) of systemic exposure of female dogs to
Lamivudine was generally slightly lower than that in male dogs. However, there was no statistically significant evidence for any sex-related differences in systemic exposure (p > 0.57). On Days 14, 28 and 42 the rate (Cmax) and extent (AUC24) of systemic exposure of dogs to Lamivudine were generally similar to those values on Day 7, however, the
Cmax values in female dogs on Days 14, 28 and 42 appeared to be lower than those values on Day 7. Overall, there was no statistically significant evidence for any time (day of sampling) related differences in the rate and extent of systemic exposure (p >
0.08). The mean values of accumulation ratios, based on AUC24 values are summarised below :
Accumulation ratio Males Females
Day l4/Day 7 1.0 1.2
Day 28/Day 7 0.9 0.8
Day 42/Day 7 1.0 1.0
The mean accumulation ratios were generally close to or less than one indicating that little or no accumulation of Lamivudine occurred following administration of HBs vaccine.
The terminal rate constants, and corresponding terminal half-lives, of Lamivudine on Days 7, 14, 28 and 42 are presented in Tables 5 - 8. The terminal rate constant, where it could be calculated ranged from 0.3239 to 0.1364 hours"' corresponding to a terminal half-life of Lamivudine of 2.1 to 5.1 hours.
Serology
Methodology
Quantitation of anti-HBs antibody was performed by ELISA using HBs (Hep 286) as coating antigen. Antigen and antibody solutions were used at 100 μl per well. Antigen was diluted at a final concentration of 1 μg/ml in PBS and was adsorbed overnight at 4°C to the wells of 96 wells microtiter plates (Maxisorb Immuno-plate, Nunc, Denmark). The plates were then incubated for lhr 30 min at 37°C with PBS containing 5% non fat powder milk and 0.1% Tween 20. Two-fold dilutions of sera (starting at 1/50 or 1/200 dilution) in PBS containing 0.5% Gloria milk and 0.1% Tween 20 were added to the HBs-coated plates and incubated for 1 hr at 37°C. The plates were washed four times with PBS 0.1% Tween 20. HRPO-conjugated anti-dog IgG (Rockland, USA) diluted 1/40000 in 0.5% non fat powder milk and 0.1% Tween 20 buffer was added to each well and incubated for 1 hr at RT. After a washing step, plates were incubated for 10 min at RT with a solution of Tetramethyl benzidine (TMB) (Biorad, USA) 2-fold diluted in Citrate buffer (0.1M pH=5.8). The reaction was stopped with H2SO4 0.5N and plates were read at 450/630 nm. ELISA titers were expressed as midpoint titers.
Results
The anti-HBs serologic response was measured by ELISA at day 0, 29 and 43. Midpoint titers are presented in the following table :
Midpoint of anti-HBs antibody titers
The mid-point average titers at the different timepoint are the respectively 25 on Day 0 (arbitrary 1/2 of first dilution), 383 on day 29 and 5321 on day 43. This clearly indicate the induction of an immune response. CONCLUSION
In conclusion, the rate and extent of systemic exposure of dogs to Lamivudine following repeated oral administration of Lamivudine at a dose level of 100 mg/dog/day appeared to be independent of the administration of HBs vaccine on Days 14, 28 and 42 o the 6-week pharmacokinetic interaction study. There was no evidence of a difference in the rate and extent of systemic exposure to Lamivudine between male and female dogs.
Administration of the pharmaccine appeared to be immunogenic and induced high circulating levels of anti-HBs antibodies, validating the use of the Beagle dog as an animal species for this PK interaction study.

Claims

1. A pharmaceutical pack comprising as active ingredients (1) an antiviral agent active against hepatitis B virus and (2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection, the active ingredients being for simultaneous or sequential use.
2. A pharmaceutical pack as claimed in claim 1 for use in the treatment of hepatitis B infections.
3. A pharmaceutical pack as claimed in claim 1 for use in the prevention of hepatitis B infections.
4. A pharmaceutical pack as claimed in any one of the preceding claims wherein the antiviral agent is a nucleoside analogue.
5. A pharmaceutical pack as claimed in claim 4 wherein the antiviral agent is selected from the group comprising; penciclovir, famciclovir or lamivudine.
6. A pharmaceutical pack as claimed in any one of claims 1 - 3 wherein the antiviral agent is a nucleotide analogue.
7. A pharmaceutical pack as claimed in claim 4 or claim 6 wherein the antiviral agent is selected from the group comprising; ganciclovir, lobucavir, adefovir, ribavirin, BMS200,475, vidarabin or ARA-AMP.
8. A pharmaceutical pack as claimed in any one of claims 1 - 3 wherein the antiviral agent is alpha - interferon.
9. A pharmaceutical pack as claimed in any one of the preceding claims wherein the vaccine active against hepatitis B comprises hepatitis B surface antigen.
10. A pharmaceutical pack as claimed in claim 9 wherein the vaccine active against hepatitis B comprises the antigen SL*.
11. A pharmaceutical pack as claimed in claim 9 wherein the vaccine active against hepatitis B comprises the 226 amino acid S antigen.
12. A pharmaceutical pack as claimed in any one of the preceding claims in which the vaccine comprises an adjuvant.
13. A pharmaceutical pack as claimed in claim 12 wherein the adjuvant is selected from the group of adjuvants comprising: 3D-MPL, QS21, a mixture of QS21 and cholesterol, a CpG oligonucleotide, aluminium hydroxide, aluminium phosphate, tocopherol, and an oil in water emulsion or a combination of two or more of the said adjuvants.
14. A pharmaceutical pack as claimed in claim 13 wherein the adjuvant comprises 3D-MPL, QS21 and an oil in water emulsion.
1 . A pharmaceutical pack as claimed in claim 14 wherein the oil in water emulsion comprises squalene, tocopherol and polyoxyethylenesorbitan monooleate (Tween 80).
16. A method of treating a patient suffering from or susceptible to Hepatitis B virus infection, comprising administering to a patient in need thereof, either simultaneously or sequentially in any order, a safe and effective amount of 1) an antiviral agent active against hepatitis B virus and 2) a vaccine for the prophylaxis and/or treatment of hepatitis B infection.
17. A method as claimed in claim 13 which comprises the use of a pharmaceutical pack according to any of claims 1 to 15
18. Use of an antiviral compound in the manufacture of a medicament for the treatment of patients already primed with a hepatitis B vaccine and suffering from a hepatitis B virus infection.
19. Use of a hepatitis B vaccine in the manufacture of a medicament for the treatment of patients already primed with an antiviral compound and suffering from a hepatitis B virus infection.
EP99965531A 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents Withdrawn EP1140163A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12
GB9900630 1999-01-12
PCT/EP1999/010295 WO2000041463A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Publications (1)

Publication Number Publication Date
EP1140163A2 true EP1140163A2 (en) 2001-10-10

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99965531A Withdrawn EP1140163A2 (en) 1999-01-12 1999-12-21 Combination of hepatitis b vaccine with antiviral agents

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
ES2298353T3 (en) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. MODIFIED WT1 PEPTIDE.
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama Methods of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (en) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Combination therapy for the treatment of chronic hepatitis b
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
CN117120088A (en) * 2021-04-07 2023-11-24 电化株式会社 Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374B1 (en) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
BR9908599A (en) * 1998-03-09 2000-11-14 Smithkline Beecham Biolog Combined vaccine compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0041463A2 *

Also Published As

Publication number Publication date
BR9916893A (en) 2001-11-20
CO5241355A1 (en) 2003-01-31
CN1391482A (en) 2003-01-15
CZ20012544A3 (en) 2002-01-16
WO2000041463A3 (en) 2000-11-09
NZ512890A (en) 2003-09-26
AR022250A1 (en) 2002-09-04
NO20013337L (en) 2001-08-17
KR20010090011A (en) 2001-10-17
CA2359110A1 (en) 2000-07-20
AU2100900A (en) 2000-08-01
AU760574B2 (en) 2003-05-15
WO2000041463A2 (en) 2000-07-20
IL144186A0 (en) 2002-05-23
ZA200105690B (en) 2002-09-25
PL349347A1 (en) 2002-07-15
JP2002534438A (en) 2002-10-15
HK1041434A1 (en) 2002-07-12
TR200102024T2 (en) 2001-12-21
NO20013337D0 (en) 2001-07-05
HUP0105070A2 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
AU760574B2 (en) Novel treatment
AU695921B2 (en) Hepatitis B vaccine
JP3470719B2 (en) Hepatitis vaccine containing 3-O-deacylated monophosphoryl lipid A
JP2002506045A (en) Combined vaccine composition
WO2015196935A1 (en) Pharmaceutical composition containing cpg oligonucleotide
JP2018512428A5 (en)
WO2014139359A1 (en) Hepatitis b vaccine
EP1850871A2 (en) Adjuvant composition comprising aluminium phosphate and 3d-mpl
Fernández et al. Five-year follow-up of chronic hepatitis B patients immunized by nasal route with the therapeutic vaccine HeberNasvac
US20110059132A1 (en) Composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
JP5138843B2 (en) New composition
MXPA01007112A (en) Novel treatment
Lu et al. Induction of antibodies to the PreS region of surface antigens of woodchuck hepatitis virus (WHV) in chronic carrier woodchucks by immunizations with WHV surface antigens
Huang et al. New advances in hepatitis B vaccination for adults
KR20210151047A (en) Immunogenic composition for the treatment of hepatitis B
CN109219449B (en) Pharmaceutical composition comprising surface antigen and nucleocapsid antigen of hepatitis b virus
JP2022516041A (en) Drug preparation for treating hepatitis B, its manufacturing method and use
US7144703B2 (en) Composition
CN113058033A (en) Pharmaceutical composition for preventing and treating hepatitis B and application thereof
Yoon Clinical Experience of HBV DNA Vaccine in Korean Patients with Chronic HBV Infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010706

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI PAYMENT 20010706

17Q First examination report despatched

Effective date: 20020620

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040302

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1041434

Country of ref document: HK